-
Copernicus Group IRB of Cary, NC, sought accreditation to validate that the 8-year-old, independent IRB and human research protection program was on the right track with its human research protection program.
-
One possible explanation for why IRB reviews of social-behavioral research pose complications and some confusion among IRBs and researchers can be found in the very different mindsets of the two parties.
-
Attendees to the 2004 Annual IRB Conference, sponsored by the Public Responsibility in Medicine and Research and held Oct. 28-31 in San Diego, will find a great deal of discussion about improving communication between IRBs and principal investigators in both biomedical and social-behavioral research areas. IRB Advisor spoke to several people who are scheduled to be PRIM&R panel members before the conference convened in late October, and this issue features stories that explore how to remove communication barriers and strategies for improving the relationship between PIs and IRBs, as well as strategies for helping the IRB process run more smoothly.
-
The relationship between IRBs and principal investigators often seems strained and adversarial, but IRB and research experts say the problems mostly can be solved with a few creative changes.
-
-
-
-
This months issue of ED Legal Letter will discuss the medicolegal risks to the physician, nurse, and hospitals associated with a patient leaving against medical advice and provide strategies to prevent patients from leaving.
-
Although diabetes mellitus is second only to asthma as the most prevalent chronic disease of childhood, the literature has very few comprehensive reviews of diabetic ketoacidosis (DKA), the most frequent cause of death in children with diabetes. The importance of an early diagnosis and appropriate management should not be underestimated. The authors provide a focused review for the ED physician for recognition and management of a child with DKA, with special attention to potentially serious complications.
-
Nitazoxanide (Alinia) is a broad spectrum antiparasitic agent, previously approved for use as an oral suspension for the treatment of cryptosporidiosis and giardiasis in children.1 It has now received FDA approval as a 500 tablet for the treatment of giardiasis in adolescents and adults.
